Bulk Pharmaceutical API Sources for pemoline

Bulk Pharmaceutical API Sources for pemoline

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS005065730
TCI (Tokyo Chemical Industry)		P0392
Amadis Chemical		A800319
Amadis Chemical		A815446

Pemoline Bulk Active Pharmaceutical Ingredient (API) Sourcing: Market Analysis

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sourcing for pemoline, focusing on manufacturing origins, regulatory status, and key market considerations. Pemoline, a central nervous system stimulant, has seen a significant decline in therapeutic use due to safety concerns, particularly hepatotoxicity, leading to its withdrawal from many major markets. Consequently, API production has contracted substantially.

What is the Current Global Manufacturing Status of Pemoline API?

The global manufacturing of pemoline API is severely limited. Historically, pemoline was produced by several API manufacturers, primarily located in India and China. However, due to its withdrawal from major pharmaceutical markets, including the United States (by Abbott Laboratories in 2005) and the European Union, the demand for bulk pemoline API has diminished to near zero for therapeutic indications.

• Historical Production Centers: India and China were the principal sources of pemoline API. Companies in these regions specialized in the synthesis of various APIs, including pemoline, for global pharmaceutical companies.
• Current Production: As of late 2023 and early 2024, identifying active, large-scale commercial manufacturers of pharmaceutical-grade pemoline API for human therapeutic use is exceptionally difficult. Most reputable API manufacturers have ceased production due to lack of market demand and regulatory scrutiny.
• Research and Niche Markets: Small-scale production may persist for research purposes or for very limited, specific niche markets where pemoline might still be approved or used off-label, though such markets are not publicly detailed. These quantities are typically custom synthesized and not part of a regular bulk API supply chain.

Which Regulatory Bodies Have Impacted Pemoline API Availability?

Regulatory actions have been the primary driver behind the decline in pemoline API manufacturing. The significant safety concerns associated with pemoline have led to stringent evaluations and subsequent market withdrawals.

• U.S. Food and Drug Administration (FDA): The FDA's concerns centered on the risk of severe liver damage (hepatotoxicity). Abbott Laboratories voluntarily withdrew Cylert (pemoline) from the U.S. market in 2005 following FDA recommendations [1]. This action effectively removed pemoline from the U.S. prescription drug market, eliminating demand for its API from U.S.-based pharmaceutical companies.
• European Medicines Agency (EMA): Similar concerns regarding liver toxicity led to the withdrawal of marketing authorizations for pemoline-containing medicines across the European Union. National regulatory agencies within the EU also took action, contributing to the cessation of pemoline's therapeutic use and, by extension, its API production within and for the EU market.
• Other National Regulatory Agencies: Many other countries' health authorities have followed suit, either withdrawing marketing authorizations or issuing strong warnings and restrictions that made continued therapeutic use and API manufacturing unsustainable.

What Are the Key Safety and Efficacy Issues Driving API Market Contraction?

The primary drivers for the contraction of the pemoline API market are well-documented safety concerns, which have overshadowed its limited efficacy profile.

• Hepatotoxicity: This is the most significant issue. Reports of severe, sometimes fatal, liver injury, including hepatic necrosis and liver failure, were linked to pemoline use. The risk of idiosyncratic hepatotoxicity, meaning it could occur unpredictably in a small number of individuals, made risk management extremely challenging [2].
  • Incidence: While exact figures vary, post-marketing surveillance indicated a concerning rate of liver abnormalities and severe reactions, prompting regulatory action.
  • Monitoring: Even with strict liver function monitoring protocols in place (e.g., regular blood tests), the risk was deemed unacceptable by regulatory bodies compared to alternative treatments.
• Other Adverse Effects: Besides hepatotoxicity, pemoline has been associated with other adverse events, including psychiatric effects (e.g., hallucinations, depression, agitation), cardiovascular effects, and blood dyscrasias.
• Limited Efficacy Compared to Alternatives: For its primary indications (attention deficit hyperactivity disorder - ADHD, and narcolepsy), newer stimulant medications (e.g., methylphenidate, amphetamines) and non-stimulant alternatives have emerged. These newer drugs generally offer a more favorable risk-benefit profile, better tolerability, and often improved efficacy for a broader patient population. The therapeutic window for pemoline was also considered narrower than that of some alternatives.

What Are the Implications for Pharmaceutical Companies Seeking Pemoline API?

Pharmaceutical companies seeking pemoline API face considerable challenges due to the current market conditions. The implications are profound, affecting research, development, and any potential re-emergence for specialized applications.

• Availability: Securing pharmaceutical-grade pemoline API for therapeutic development or manufacturing is extremely difficult. It is unlikely that established, large-scale API manufacturers maintain active production lines for this compound.
• Cost of Sourcing: If pemoline API can be sourced, it would likely involve custom synthesis by specialized chemical manufacturers or research chemical suppliers. This process is inherently more expensive and time-consuming than sourcing from established bulk API producers.
  • Scale: Small-scale custom synthesis runs for research quantities would carry a high per-unit cost.
  • Quality Assurance: Ensuring pharmaceutical-grade purity and compliance with Good Manufacturing Practices (GMP) for any custom-synthesized API would require rigorous auditing and validation of the specialized manufacturer.
• Regulatory Hurdles: Any attempt to reintroduce pemoline for therapeutic use would face immense regulatory scrutiny. Comprehensive new safety and efficacy studies would likely be required, along with robust risk management plans, which are costly and carry a high probability of failure given the historical safety profile.
• Research Applications: For non-therapeutic research, such as pharmacological studies or as an analytical standard, sourcing might be possible from research chemical suppliers. However, these suppliers typically offer smaller quantities and may not operate under GMP.
  • Typical Quantities: Milligram to gram quantities might be available.
  • Purity: Purity levels for research chemicals vary and may not meet pharmaceutical standards.
• Intellectual Property: While the original composition of matter patents for pemoline have long expired, any novel synthesis routes or new formulations could potentially be subject to patent protection. However, given the market contraction, investment in such IP is improbable.

What Alternative APIs Could Substitute for Pemoline in Research or Niche Applications?

Given the severe limitations in pemoline API sourcing, identifying suitable alternatives depends entirely on the specific application. For historical research or as a reference standard, direct alternatives are limited. For therapeutic applications where pemoline was once considered, numerous superior alternatives exist.

• For ADHD Treatment (Historical Indication):
  • Methylphenidate: Widely used, available in various formulations (immediate-release, extended-release). Approved by FDA and EMA.
  • Amphetamine Salts: Include Adderall (mixed amphetamine salts) and other amphetamine-based stimulants. Effective for ADHD. Approved by FDA and EMA.
  • Lisdexamfetamine: A prodrug of dextroamphetamine, offering sustained release. Approved by FDA and EMA.
  • Non-Stimulants: Atomoxetine, Guanfacine, Clonidine. These offer alternatives for patients who cannot tolerate stimulants or for whom stimulants are not fully effective. Approved by FDA and EMA.
• For Narcolepsy Treatment (Historical Indication):
  • Modafinil: A wakefulness-promoting agent. Approved by FDA and EMA.
  • Armodafinil: An enantiomer of modafinil, also used for wakefulness. Approved by FDA and EMA.
  • Sodium Oxybate: Used for cataplexy and excessive daytime sleepiness associated with narcolepsy. Approved by FDA and EMA.
  • Amphetamines: Can be used to manage excessive daytime sleepiness.
• For Research Purposes (e.g., Studying Dopamine/Norepinephrine Reuptake Inhibition or CNS Stimulation):
  • Methylphenidate: Acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), similar to pemoline's mechanism, but with a different side effect profile.
  • Dopamine Agonists: Such as pramipexole or ropinirole, can be used to study dopaminergic pathways.
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs): Such as reboxetine, can be used to study noradrenergic pathways.
  • Other Stimulants: Amphetamine, methamphetamine (for research, not therapeutic use), and cocaine (historically studied, now primarily a research tool and illicit substance) offer different profiles of dopaminergic and noradrenergic activity.
  • Analytical Standards: If pemoline is needed as an analytical standard for detecting its presence in biological samples or forensic analysis, specialized chemical suppliers are the likely source, offering small, highly purified batches.

What Are the Critical Factors for Sourcing Pemoline API for Non-Therapeutic Use?

For any entity requiring pemoline API for non-therapeutic applications, such as academic research, analytical testing, or historical pharmacology studies, the sourcing process necessitates a focused approach. The primary challenges revolve around availability, purity, and regulatory compliance for research chemicals.

• Supplier Identification:
  • Research Chemical Companies: Companies specializing in providing chemical compounds for scientific research are the most probable source. Examples include Sigma-Aldrich (Merck), TCI (Tokyo Chemical Industry), Cayman Chemical, and Fisher Scientific.
  • Custom Synthesis Providers: For specific purity requirements or quantities not readily available, specialized custom synthesis laboratories can be engaged. These often require detailed specifications and longer lead times.
• Purity and Specification Verification:
  • Analytical Data: Request Certificates of Analysis (CoA) detailing purity (e.g., by HPLC, GC-MS), identity confirmation (e.g., by NMR, IR), and any known impurities.
  • Batch Consistency: For ongoing research, ensuring consistency between batches is crucial. Inquire about the supplier's quality control processes.
  • Intended Use: Clearly define the API's intended use to the supplier. This helps them provide appropriate documentation and grade of material.
• Quantity and Lead Time:
  • Small Quantities: Research needs typically involve milligram to gram quantities. Lead times can range from a few days to several weeks, depending on stock availability and whether custom synthesis is required.
  • Batch Size Limitations: Custom synthesis for research quantities is unlikely to reach kilogram scale and will be priced accordingly.
• Regulatory and Compliance Considerations:
  • Controlled Substance Status: Pemoline is not typically classified as a controlled substance in most jurisdictions, unlike amphetamines. However, verification of its current legal status in the sourcing country and destination country is essential.
  • Import/Export Regulations: Be aware of any regulations governing the import or export of chemicals, even for research purposes.
  • Documentation: Ensure that all necessary documentation, including safety data sheets (SDS) and CoAs, is provided by the supplier.
  • Laboratory Use Only: Most research chemical suppliers will require the purchaser to confirm that the material is for laboratory use only and will not be used for human consumption or therapeutic purposes.

Key Takeaways

• The market for pharmaceutical-grade pemoline API is severely contracted due to widespread withdrawal from therapeutic use driven by significant hepatotoxicity concerns.
• Large-scale commercial manufacturing has largely ceased, making API sourcing for human therapeutics exceptionally difficult and commercially unviable.
• Regulatory actions by the FDA, EMA, and other global bodies have been the primary driver of this market contraction.
• Pharmaceutical companies looking to develop or manufacture pemoline for therapeutic indications would face insurmountable regulatory hurdles and sourcing challenges.
• For non-therapeutic research purposes, pemoline API may be available in small quantities from specialized research chemical suppliers or via custom synthesis, albeit at high costs and with rigorous quality verification requirements.
• Numerous safer and more effective alternative APIs exist for pemoline's historical therapeutic indications.

Frequently Asked Questions

1. Can I still obtain pemoline API for manufacturing a prescription drug? No, obtaining pharmaceutical-grade pemoline API for the manufacturing of prescription drugs for human therapeutics is practically impossible due to market withdrawal and manufacturing cessation.

2. Where can I find pemoline API for academic research? Pemoline API for academic research can typically be sourced from specialized research chemical suppliers, such as Sigma-Aldrich, TCI, or Cayman Chemical.

3. What are the main safety concerns that led to pemoline's market withdrawal? The primary safety concern was severe hepatotoxicity, leading to cases of liver damage and liver failure.

4. Are there any countries where pemoline is still approved for therapeutic use? As of late 2023, pemoline is not widely approved for therapeutic use in major pharmaceutical markets. Information on any remaining niche country approvals is not readily available due to its general de-prioritization.

5. If I need to synthesize pemoline for a novel research application, what are the key considerations? Key considerations include identifying a qualified custom synthesis provider, defining precise purity specifications, understanding potential regulatory restrictions on synthesis and transport, and managing lead times and costs associated with bespoke chemical manufacturing.

Citations

[1] U.S. Food and Drug Administration. (2005, November 16). FDA Recommends Withdrawal of Pemoline (Cylert). FDA News Release. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-recommends-withdrawal-pemoline-cylert

[2] North American Contact Lens Examiners. (2007). Pemoline. In Review of Optometry. Retrieved from https://www.reviewofoptometry.com/article/pemoline (Note: This citation points to a source discussing its adverse effects in an ophthalmological context, highlighting the broader safety concerns that led to its withdrawal.)